From: The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
Study | Drugs | Composite outcomea | Progression of albuminuria | dSCr | Renal death | ESKD | 40% eGFR reduction |
---|---|---|---|---|---|---|---|
Canagliflozin | 5.5 | 89.4 | 1.2 | Â | 0.4 | 5.3 | |
Placebo | 9.0 | 128.7 | 2.4 | Â | 0.6 | 8.7 | |
P value | 0.3868 | 0.0184 | Â | Â | Â | Â | |
CREDENCE [70] | Canagliflozin | 11.1 | Â | 5.4 | 0.1 | 5.3 | 3.5 |
Placebo | 15.5 | Â | 8.5 | 0.2 | 7.5 | 5.7 | |
P value | 0.00001 |  | < 0.001 |  | 0.002 |  | |
DECLARE–TIMI 58 [93] | Dapagliflozin | 1.5 |  |  | 0.1 | 0.1 | 1.4 |
Placebo | 2.6 | Â | Â | 0.1 | 0.2 | 2.5 | |
P value | < 0.0001 |  |  | 0.32 | 0.013 | < 0.0001 | |
DAPA-CKD [122] | Dapagliflozin | 6.6 |  |  | < 0.1 | 5.1 | 5.2 |
Placebo | 11.3 | Â | Â | 0.3 | 7.5 | 9.3 | |
P value | < 0.001 |  |  |  |  |  | |
EMPEROR-Reduced [68] | Empagliflozin | 1.6 | Â | Â | Â | Â | Â |
Placebo | 3.1 | Â | Â | Â | Â | Â | |
P value |  |  |  |  |  | < 0.001 | |
EMPA-REG OUTCOME [86] | Empagliflozin | 1.7 | 11.2 | 1.5 | Â | Â | Â |
Placebo | 3.1 | 16.2 | 2.6 | Â | Â | Â | |
P value | < 0.001 | < 0.001 | < 0.001 |  |  |  | |
VERTIS CV [11] | Ertugliflozin | 3.2 | Â | 3.1 | 0 | Â | Â |
Placebo | 3.9 | Â | 3.8 | 0 | Â | Â |